U of M trial finds hydroxychloroquine not an effective COVID-19 treatment

By | June 3, 2020

WINNIPEG — A new study involving the University of Manitoba says hydroxychloroquine is not an effective treatment to prevent the development of COVID-19.

The results of the study, released Wednesday, comes following a trial of the drug in the United States, Manitoba, Quebec, and Ontario.

The University of Manitoba participated in the study, which included McGill University, the University of Minnesota, and the University of Alberta.

“While we had hope this drug would work in this context, our study demonstrates that hydroxychloroquine is no better than placebo when used as post-exposure prophylaxis within 4 days of exposure to someone infected with the new coronavirus,” said Dr. Todd Lee, associate professor of medicine in the Division of Infectious Diseases at McGill University, in a statement.

The trial involved 821 asymptomatic adults with household or healthcare exposure to someone with confirmed COVID-19 receiving Hydroxychloroquine or a placebo, four days following exposure.

According to the study, 107 of 821 of participants developed COVID-19, either confirmed with a test or symptomatically compatible disease, over the 14 days of follow-up. The study included both confirmed cases and probable cases, due to some lack of availability of diagnostic testing in the United States.

Among those who received hydroxychloroquine, 49 developed the disease, or compatible symptoms, such as fever or cough. A total of 58 people in the group that received the placebo developed COVID-19.

Two people were hospitalized, the study said, with one hospitalized in the hydroxychloroquine group, and one in the placebo group.

The study said no serious treatment-related adverse reactions were reported, including any heart arrhythmia. It adds more research and trials need to be conducted on the effectiveness of hydroxychloroquine.

The drug has been in the news in recent weeks as U.S. President Donald Trump told reporters he was taking the drug, despite it being unproven as a treatment for COVID-19.

The study was published in the New England Journal of Medicine.

View original article here Source